Janssen's Darzalex data delivers at ASH

12 December 2017

The pressure to show progress in blood cancers at this year’s American Society of Hematology (ASH) Annual Meeting has been intense, and Janssen has not missed out with its data on Imbruvica (ibrutinib) and now Darzalex (daratumumab).

On Tuesday, the Johnson & Johnson (NYSE: JNJ) unit presented data on Darzalex that highlights its versatility and potential to be the foundational therapy across all lines of multiple myeloma (MM).

New data that was accepted as one of only six late-breakers at ASH and featured in the event’s official press conference showed what happened when Darzalex was added to Takeda's (TYO: 4502) Velcade (bortezomib), along with melphalan and prednisone. The Darzalex arm in this Phase III study significantly improved clinical outcomes, including reducing the risk of disease progression or death by 50%, compared to the other three alone.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK